Der Internist

, Volume 50, Issue 1, pp 27–35 | Cite as

Das Phäochromozytom – noch immer eine Herausforderung

Schwerpunkt: Therapierefraktäre und sekundäre arterielle Hypertonie
First Online:

Zusammenfassung

Das Phäochromozytom ist ein seltener, in der Regel gutartiger, katecholaminproduzierender Tumor des Nebennierenmarks oder der Paraganglien. Die tumorbedingte Hormonwirkung führt zur Leitsymptomatik mit Palpitationen, Schweißattacken und Kopfschmerzen sowie arterieller Hypertonie. Biochemisch wird die Diagnose durch die Bestimmung der Katecholamine und fraktionierten Metanephrine im 24-h-Sammelurin oder der freien Metanephrine im Plasma gesichert. Als bildgebende Verfahren werden die Computertomographie und Magnetresonanztomographie der Nebennieren eingesetzt, komplementär die 123Jod-MIBG-Szintigraphie und 18Fluor-Dopa-Positronenemissionstomographie. Da etwa 24% der scheinbar sporadischen Phäochromozytome familiären Ursprungs sind, ist die molekulargenetische Untersuchung unverzichtbarer Bestandteil der Diagnostik. Die endoskopische und organerhaltende Chirurgie ist nach ausreichender präoperativer α-Rezeptorblockade als kurativer Ansatz die Therapie der Wahl. Aufgrund des Rezidiv- und Malignitätsrisikos sind regelmäßige Nachsorgeuntersuchungen unverzichtbar.

Schlüsselwörter

Phäochromozytom Paragangliom Katecholamine Hypertonie 

Pheochromocytoma – still a challenge

Abstract

Pheochromocytomas are rare, mostly benign catecholamine-producing tumors arising from the chromaffin cells of the adrenal medulla or in the paraganglia. Clinical presentation is highly variable but typically with hypertension, severe headaches, palpitations and sweating. Biochemical testing by 24 h urinary fractioned metanephprines or catecholamines and plasma free metanephrines as the most sensitive screening approach, confirms the catecholamine excess. Computed tomography scan and magnetic resonance imaging of the adrenal glands and abdomen as well as functional imaging with 123Iod-MIBG scintigraphy and 18F-dopa positron emission tomography are used for tumor localization. Because approximately a quarter of tumors develop secondary to germ-line mutations, screening for genetic alterations is important. The therapy of choice is the endoscopic adrenal sparing surgery following preoperative α-blockade. Regular follow-up remains essential due to possible recurrence and malignancy.

Keywords

Pheochromocytoma Paraganglioma Catecholamines Hypertension 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Amar L, Bertherat J, Baudin E et al. (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23: 8812–8818PubMedCrossRefGoogle Scholar
  2. 2.
    Averbuch SD, Steakley CS, Young RC et al. (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med 109: 267–273PubMedGoogle Scholar
  3. 3.
    Baguet JP, Hammer L, Mazzuco TL et al. (2004) Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 150: 681–686PubMedCrossRefGoogle Scholar
  4. 4.
    Bausch B, Borozdin W, Neumann HP (2006) Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 354: 2729–2731PubMedCrossRefGoogle Scholar
  5. 5.
    Benn DE, Gimenez-Roqueplo AP, Reilly JR et al. (2006) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91: 827–836PubMedCrossRefGoogle Scholar
  6. 6.
    Eisenhofer G, Bornstein SR, Brouwers FM et al. (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11: 423–436PubMedCrossRefGoogle Scholar
  7. 7.
    Eisenhofer G, Huynh TT, Pacak K et al. (2004) Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 11: 897–911PubMedCrossRefGoogle Scholar
  8. 8.
    Eisenhofer G, Keiser H, Friberg P et al. (1998) Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 83: 2175–2185PubMedCrossRefGoogle Scholar
  9. 9.
    Eisenhofer G, Lenders JW, Goldstein DS et al. (2005) Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 51: 735–744PubMedCrossRefGoogle Scholar
  10. 10.
    Fitzgerald PA, Goldsby RE, Huberty JP et al. (2006) Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 1073: 465–490PubMedCrossRefGoogle Scholar
  11. 11.
    Furuta N, Kiyota H, Yoshigoe F et al. (1999) Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 6: 119–124PubMedCrossRefGoogle Scholar
  12. 12.
    Hoegerle S, Ghanem N, Altehoefer C et al. (2003) 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30: 689–694PubMedGoogle Scholar
  13. 13.
    Hoegerle S, Nitzsche E, Altehoefer C et al. (2002) Pheochromocytomas: detection with 18F DOPA whole body PET – initial results. Radiology 222: 507–512PubMedCrossRefGoogle Scholar
  14. 14.
    Ilias I, Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89: 479–491PubMedCrossRefGoogle Scholar
  15. 15.
    Ito T, Imai T, Kikumori T et al. (2006) Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result. Surg Today 36: 961–965PubMedCrossRefGoogle Scholar
  16. 16.
    Jimenez C, Cote G, Arnold A, Gagel RF (2006) Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 91: 2851–2858PubMedCrossRefGoogle Scholar
  17. 17.
    Khorram-Manesh A, Ahlman H, Nilsson O et al. (2004) Mortality associated with pheochromocytoma in a large Swedish cohort. Eur J Surg Oncol 30: 556–559PubMedCrossRefGoogle Scholar
  18. 18.
    Lenders JW, Pacak K, Walther MM et al. (2002) Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287: 1427–1434PubMedCrossRefGoogle Scholar
  19. 19.
    Manger WM, Eisenhofer G (2004) Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep 6: 477–484PubMedCrossRefGoogle Scholar
  20. 20.
    Manger WM, Gifford RW (2002) Pheochromocytoma. J Clin Hypertens (Greenwich) 4: 62–72Google Scholar
  21. 21.
    Mannelli M, Ianni L, Cilotti A, Conti A (1999) Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141: 619–624PubMedCrossRefGoogle Scholar
  22. 22.
    McNicol AM (2006) Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas. Endocr Pathol 17: 329–336PubMedCrossRefGoogle Scholar
  23. 23.
    McWhinney SR, Pasini B, Stratakis CA (2007) Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med 357: 1054–1056PubMedCrossRefGoogle Scholar
  24. 24.
    Neumann HP, Bausch B, McWhinney SR et al. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346: 1459–1466PubMedCrossRefGoogle Scholar
  25. 25.
    Neumann HP, Berger DP, Sigmund G et al. (1993) Pheochromocytomas, multiple endocrine neoplasia type 2 and von Hippel-Lindau disease. N Engl J Med 329: 1531–1538PubMedCrossRefGoogle Scholar
  26. 26.
    Neumann HP, Pawlu C, Peczkowska M et al. (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292: 943–951PubMedCrossRefGoogle Scholar
  27. 27.
    Neumann HP, Vortmeyer A, Schmidt D et al. (2007) Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med 357: 1311–1315PubMedCrossRefGoogle Scholar
  28. 28.
    Opocher G, Conton P, Schiavi F et al. (2005) Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1 Review. Fam Cancer 4: 13–16PubMedCrossRefGoogle Scholar
  29. 29.
    Pacak K, Ilias I, Adams KT, Eisenhofer G (2005) Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 257: 60–68PubMedCrossRefGoogle Scholar
  30. 30.
    Pawlu C, Bausch B, Neumann HP (2005) Mutations of the SDHB and SDHD genes. Fam Cancer 4: 49–54PubMedCrossRefGoogle Scholar
  31. 31.
    Pawlu C, Bausch B, Reisch N, Neumann HP (2005) Genetic testing for pheochromocytoma-associated syndromes. Ann Endocrinol (Paris) 66: 178–185Google Scholar
  32. 32.
    Plouin PF, Degoulet P, Tugaye A et al. (1981) Screening for phaeochromocytoma: in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma. Nouv Presse Med 10: 869–872PubMedGoogle Scholar
  33. 33.
    Reisch N, Peczkowska M, Januszewicz A, Neumann HP (2006) Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens 24: 2331–2339PubMedCrossRefGoogle Scholar
  34. 34.
    Rose B, Matthay KK, Price D et al. (2003) High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98: 239–248PubMedCrossRefGoogle Scholar
  35. 35.
    Safford SD, Coleman RE, Gockerman JP et al. (2003) Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956–962PubMedCrossRefGoogle Scholar
  36. 36.
    Salmenkivi K, Heikkila P, Haglund C, Arola J (2004) Malignancy in pheochromocytomas. APMIS 112: 551–559PubMedCrossRefGoogle Scholar
  37. 37.
    Scholz T, Eisenhofer G, Pacak K et al. (2007) Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92: 1217–1225PubMedCrossRefGoogle Scholar
  38. 38.
    Tada K, Okuda Y, Yamashita K (1998) Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine combination chemotherapy and alpha-methyl-p-tyrosine to control hypercatecholaminemia. Horm Res 49: 295–297PubMedCrossRefGoogle Scholar
  39. 39.
    Tauzin-Fin P, Sesay M, Gosse P, Ballanger P (2004) Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma. Br J Anaesth 92: 512–517PubMedCrossRefGoogle Scholar
  40. 40.
    Timmers HJ, Hadi M, Carrasquillo JA et al. (2007) The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 48: 1599–1606PubMedCrossRefGoogle Scholar
  41. 41.
    Tsvetov G, Shimon I, Benbassat C (2007) Adrenal incidentaloma: clinical characteristics and comparison between patients with and without extraadrenal malignancy. J Endocrinol Invest 30: 647–652PubMedGoogle Scholar
  42. 42.
    van der Harst E, de Herder WW, Bruining HA et al. (2001) [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab 86: 685–693CrossRefGoogle Scholar
  43. 43.
    Vanharanta S, Buchta M, McWhinney SR et al. (2004) Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 74: 153–159PubMedCrossRefGoogle Scholar
  44. 44.
    Walz MK, Peitgen K, Diesing D et al. (2004) Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasias. World J Surg 28: 1323–1329PubMedCrossRefGoogle Scholar
  45. 45.
    Walz MK, Peitgen K, Neumann HP et al. (2002) Endoscopic treatment of solitary, bilateral, multiple and recurrent pheochromocytomas and paragangliomas. World J Surg 26: 1005–1012PubMedCrossRefGoogle Scholar
  46. 46.
    Walz MK, Peitgen K, Walz MV et al. (2001) Posterior retroperitoneoscopic adrenalectomy: lessons learned within five years. World J Surg 25: 728–734PubMedCrossRefGoogle Scholar
  47. 47.
    Walz MK, Petersenn S, Koch JA et al. (2005) Endoscopic treatment of large primary adrenal tumours. Br J Surg 92: 719–723PubMedCrossRefGoogle Scholar
  48. 48.
    Yeo H, Roman S (2005) Pheochromocytoma and functional paraganglioma. Curr Opin Oncol 17: 13–18PubMedCrossRefGoogle Scholar
  49. 49.
    Yip L, Lee JE, Shapiro SE et al. (2004) Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198: 525–534PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  • N. Reisch
    • 1
    • 2
  • M.K. Walz
    • 3
  • Z. Erlic
    • 4
  • H.P.H. Neumann
    • 4
  1. 1.Medizinische Klinik – InnenstadtKlinikum der Universität MünchenMünchenDeutschland
  2. 2.Endocrinolgy and MetabolismInstitute of Biomedical Research, University of BirminghamBirminghamGroßbritannien
  3. 3.Klinik für Chirurgie und Zentrum für Minimal Invasive ChirurgieKliniken Essen-MitteEssenDeutschland
  4. 4.Abteilung Innere Medizin IV, Medizinische UniversitätsklinikUniversitätsklinikum FreiburgFreiburg i. Br.Deutschland

Personalised recommendations